Literature DB >> 15374946

Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer.

Prashant R Nambiar1, Masako Nakanishi, Rishi Gupta, Evelyn Cheung, Ali Firouzi, Xiao-Jun Ma, Christopher Flynn, Mei Dong, Kishore Guda, Joel Levine, Rajiv Raja, Luke Achenie, Daniel W Rosenberg.   

Abstract

To determine whether cancer risk is related to histopathological features of preneoplastic aberrant crypt foci (ACF), gene expression analysis was performed on ACF from two mouse strains with differing tumor sensitivity to the colonotropic carcinogen, azoxymethane. ACF from sensitive A/J mice were considered at high risk, whereas ACF from resistant AKR/J mice were considered at low risk for tumorigenesis. A/J and AKR/J mice received weekly injections of azoxymethane (10 mg/kg body weight), and frozen colon sections were prepared 6 weeks later. Immunohistochemistry was performed using biomarkers associated with colon cancer, including adenomatous polyposis coli, beta-catenin, p53, c-myc, cyclin D1, and proliferating cell nuclear antigen. Hyperplastic ACF, dysplastic ACF, microadenomas, adjacent normal-appearing epithelium, and vehicle-treated colons were laser captured, and RNA was linearly amplified (LCM-LA) and subjected to cDNA microarray-based expression analysis. Patterns of gene expression were identified using adaptive centroid algorithm. ACF from low- and high-risk colons were not discriminated by immunohistochemistry, with the exception of membrane staining of beta-catenin. To develop genetic signatures that predict cancer risk, LCM-LA RNA from ACF was hybridized to cDNA arrays. Of 4896 interrogated genes, 220 clustered into six broad clusters. A total of 226 and 202 genes was consistently altered in lesions from A/J and AKR/J mice, respectively. Although many alterations were common to both strains, expression profiles stratified high- and low- risk lesions. These data demonstrate that ACF with distinct tumorigenic potential have distinguishing molecular features. In addition to providing insight into colon cancer promotion, our data identify potential biomarkers for determining colon cancer risk in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374946     DOI: 10.1158/0008-5472.CAN-04-0933

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Multifaceted roles of PGE2 in inflammation and cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Semin Immunopathol       Date:  2012-09-21       Impact factor: 9.623

2.  IER3 supports KRASG12D-dependent pancreatic cancer development by sustaining ERK1/2 phosphorylation.

Authors:  Maria Noé Garcia; Daniel Grasso; Maria Belen Lopez-Millan; Tewfik Hamidi; Celine Loncle; Richard Tomasini; Gwen Lomberk; Françoise Porteu; Raul Urrutia; Juan L Iovanna
Journal:  J Clin Invest       Date:  2014-09-24       Impact factor: 14.808

3.  Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity.

Authors:  Masako Nakanishi; Antoine Menoret; Takuji Tanaka; Shingo Miyamoto; David C Montrose; Anthony T Vella; Daniel W Rosenberg
Journal:  Cancer Prev Res (Phila)       Date:  2011-05-16

Review 4.  Roles of cPLA2alpha and arachidonic acid in cancer.

Authors:  Masako Nakanishi; Daniel W Rosenberg
Journal:  Biochim Biophys Acta       Date:  2006-09-15

5.  Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model.

Authors:  Scott C Borinstein; Melissa Conerly; Slavomir Dzieciatkowski; Swati Biswas; M Kay Washington; Patty Trobridge; Steve Henikoff; William M Grady
Journal:  Mol Carcinog       Date:  2010-01       Impact factor: 4.784

6.  Gene expression profile and genomic alterations in colonic tumours induced by 1,2-dimethylhydrazine (DMH) in rats.

Authors:  Angelo Pietro Femia; Cristina Luceri; Simona Toti; Augusto Giannini; Piero Dolara; Giovanna Caderni
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

7.  Ablation of gly96/immediate early gene-X1 (gly96/iex-1) aggravates DSS-induced colitis in mice: role for gly96/iex-1 in the regulation of NF-kappaB.

Authors:  Christian Sina; Alexander Arlt; Philip Rosenstiel; Heiner Schäfer; Olga Gavrilova; Emilie Midtling; Marie-Luise Kruse; Susanne Sebens Müerköster; Rajiv Kumar; Ulrich R Fölsch; Stefan Schreiber
Journal:  Inflamm Bowel Dis       Date:  2010-02       Impact factor: 5.325

8.  Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon.

Authors:  Shelly R Calcagno; Shuhua Li; Migdalisel Colon; Pamela A Kreinest; E Aubrey Thompson; Alan P Fields; Nicole R Murray
Journal:  Int J Cancer       Date:  2008-06-01       Impact factor: 7.396

Review 9.  Immediate early response gene X-1, a potential prognostic biomarker in cancers.

Authors:  Mei X Wu; Irina V Ustyugova; Liping Han; Oleg E Akilov
Journal:  Expert Opin Ther Targets       Date:  2013-02-04       Impact factor: 6.902

Review 10.  Aberrant crypt foci as precursors in colorectal cancer progression.

Authors:  Frank A Orlando; Dongfeng Tan; Juan D Baltodano; Thaer Khoury; John F Gibbs; Victor J Hassid; Bestoun H Ahmed; Sadir J Alrawi
Journal:  J Surg Oncol       Date:  2008-09-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.